IQVIA (NYSE:IQV) Stock Price Down 8.5% – What’s Next?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price fell 8.5% on Thursday . The stock traded as low as $159.39 and last traded at $160.2660. 245,766 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,929,299 shares. The stock had previously closed at $175.21.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on IQV shares. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday. UBS Group reduced their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research report on Friday, March 6th. Finally, Citigroup reduced their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Buy” and a consensus target price of $226.63.

IQVIA Trading Down 8.8%

The firm has a 50-day moving average of $170.28 and a 200-day moving average of $203.30. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market capitalization of $27.10 billion, a P/E ratio of 20.32, a price-to-earnings-growth ratio of 1.75 and a beta of 1.39.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period last year, the company earned $3.12 EPS. IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently bought and sold shares of IQV. Ameliora Wealth Management Ltd. bought a new position in IQVIA during the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. grew its position in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new position in IQVIA during the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $27,000. Finally, CrossGen Wealth LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $28,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.